These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17982376)

  • 1. [Clinical assessment of drug safety].
    Imbs JL; Welsch M
    Ann Pharm Fr; 2007 Sep; 65(5):298-302. PubMed ID: 17982376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses.
    Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C
    Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004.
    Beyens MN; Guy C; Mounier G; Laporte S; Ollagnier M
    Drug Saf; 2008; 31(11):1017-26. PubMed ID: 18840021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causality assessment in pharmacovigilance: The French method and its successive updates.
    Miremont-Salamé G; Théophile H; Haramburu F; Bégaud B
    Therapie; 2016 Apr; 71(2):179-86. PubMed ID: 27080836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacovigilance in practice].
    Spreux A; Baldin B; Chichmanian RM
    Transfus Clin Biol; 1999 Jul; 6(4):254-9. PubMed ID: 10472690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specialist Cohort Event Monitoring studies: a new study method for risk management in pharmacovigilance.
    Layton D; Shakir SA
    Drug Saf; 2015 Feb; 38(2):153-63. PubMed ID: 25564333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Summarizing of medicinal alerts in Ivory Coast from 2001 till 2010].
    N'Guessan-Irié AG; Yavo JC; Guillaume Amari AS; Yapi AD
    Therapie; 2012; 67(3):251-6. PubMed ID: 22874492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Social Media Listening for Routine Post-Marketing Safety Surveillance.
    Powell GE; Seifert HA; Reblin T; Burstein PJ; Blowers J; Menius JA; Painter JL; Thomas M; Pierce CE; Rodriguez HW; Brownstein JS; Freifeld CC; Bell HG; Dasgupta N
    Drug Saf; 2016 May; 39(5):443-54. PubMed ID: 26798054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cosmetovigilance: a French pharmacovigilance system for cosmetics developed by the French health products safety agency. A proposal for the future].
    Tissier MH; Lepagnol F
    Therapie; 2002; 57(3):273-82. PubMed ID: 12422542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of etifoxine: A French pharmacovigilance survey.
    Cottin J; Gouraud A; Jean-Pastor MJ; Dautriche AD; Boulay C; Geniaux H; Auffret M; Bernard N; Descotes J; Vial T
    Fundam Clin Pharmacol; 2016 Apr; 30(2):147-52. PubMed ID: 26588183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The French pharmacovigilance system: structure and missions].
    Welsch M; Alt M; Richard MH; Imbs JL
    Presse Med; 2000 Jan; 29(2):102-6. PubMed ID: 10682040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Official systems of pharmacovigilance in France and in Spain. Comparison of spontaneous reporting in two regional centers: Pays Basque and Bordeaux].
    Aguirre C; Haramburu F
    Therapie; 1995; 50(6):563-9. PubMed ID: 8745957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Child overdose: the value of the French pharmacovigilance causality assessment method.
    Rajab M; Lagier G; Eftekhari P; Ginisty S; Bazire A; Garnier R
    Therapie; 2004; 59(6):603-6. PubMed ID: 15789822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug safety and big clinical data: Detection of drug-induced anaphylactic shock events.
    Bouzillé G; Osmont MN; Triquet L; Grabar N; Rochefort-Morel C; Chazard E; Polard E; Cuggia M
    J Eval Clin Pract; 2018 Jun; 24(3):536-544. PubMed ID: 29532572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting.
    Mascolo A; Scavone C; Sessa M; di Mauro G; Cimmaruta D; Orlando V; Rossi F; Sportiello L; Capuano A
    Pharmacol Res; 2017 Sep; 123():122-129. PubMed ID: 28694146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Educational material as part of risk minimisation].
    Heymans L; Huber M; Paeschke N; Palissa H; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Sep; 61(9):1088-1092. PubMed ID: 30083947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.